Detection and Treatment of Molecular Relapse in Acute Myeloid
Leukemia with RUNX1 (AML1), CBFB or MLL Gene Translocations.
Frequent Quantitative Monitoring of Molecular Markers in
Different Compartments and Correlation with WT1 Gene Expression

J 2009

Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1 (AML1), CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression

Základní údaje

Originální název

Název česky

Detekce a léčba molekulárního relapsu u akutní myeloidní leukemie s traslokacemi genů RUNX1 (AML1), CBFB nebo MLL. Časté kvantitativní monit molekulárních markerů v různých kompartmentech a korelace s expresí geni WT1

Vydání

Experimental Hematology, Int Soc for Exper Hematol, 2009, 0301-472X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.106

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

UT WoS

000266458200002

Klíčová slova česky

akutní myeloidní leukemie - zbytková nemoc - molekulární relaps - léčba

Klíčová slova anglicky

acute myeloid leukemia - minimal residual disease - molecular relapse - treatment

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 6. 2009 20:58, prof. MUDr. Michael Doubek, Ph.D.

Anotace

V originále

Objective. Our hypothesis was that by frequent monitoring the minimal residual disease (MRD) in different compartments (peripheral blood, PB; bone marrow, BM; CD34+BM cells; and CD34-BM cells), we would be able to find patterns which could predict a clinical relapse of acute myeloid leukemia (AML) and discover whether it is possible to treat the disease in the phase of molecular relapse. Methods. In our cohort of patients, frequent MRD monitoring was performed in all phases of AML treatment using RQ PCR for fusion transcripts (CBFB/MYH11, RUNX1/RUNX1T1, fusion transcripts of MLL gene) and for the WT1 gene. In 79 AML patients and 6 healthy volunteers, 2664 samples were examined. Results. We found a strong correlation between the fusion transcripts levels in BM and PB. The correlation between WT1 PB and BM levels was far less satisfactory. We were not able to ascertain any WT1 level as a confidential marker of molecular remission in either compartment. In relapsed patients, the time period of molecular to hematological relapse was 8–79 days. In the case of molecular relapse, the highest levels of fusion transcripts were in the CD34+BM cells. Twelve patients were treated for 21 molecular relapses; two-thirds of the patient had favorable treatment response. Conclusion. Frequent quantitative monitoring of fusion transcripts (in contrast to WT1) is useful for a reliable prediction of hematological relapse in AML patients. The treatment of molecular relapse of AML may be successful.

Návaznosti

MSM0021622430, záměr

Název: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Citovat

Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1 (AML1), CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression. Experimental Hematology. Int Soc for Exper Hematol, 2009, roč. 37, s. 659-672, 13 s. ISSN 0301-472X.

@article{835058,
   keywords = {acute myeloid leukemia - minimal residual disease - molecular relapse - treatment},
   language = {eng},
   issn = {0301-472X},
   journal = {Experimental Hematology},
   title = {Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1 (AML1), CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression},
   volume = {37},
   year = {2009}
}

TY  - JOUR
ID  - 835058
PY  - 2009
TI  - Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1 (AML1), CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression
JF  - Experimental Hematology
VL  - 37
SP  - 659-672
EP  - 659-672
PB  - Int Soc for Exper Hematol
SN  - 0301472X
KW  - acute myeloid leukemia - minimal residual disease - molecular relapse - treatment
N2  - Objective. Our hypothesis was that by frequent monitoring the minimal residual disease (MRD) in different compartments (peripheral blood, PB; bone marrow, BM; CD34+BM cells; and CD34-BM cells), we would be able to find patterns which could predict a clinical relapse of acute myeloid leukemia (AML) and discover whether it is possible to treat the disease in the phase of molecular relapse. Methods. In our cohort of patients, frequent MRD monitoring was performed in all phases of AML treatment using RQ PCR for fusion transcripts (CBFB/MYH11, RUNX1/RUNX1T1, fusion transcripts of MLL gene) and for the WT1 gene. In 79 AML patients and 6 healthy volunteers, 2664 samples were examined. Results. We found a strong correlation between the fusion transcripts levels in BM and PB. The correlation between WT1 PB and BM levels was far less satisfactory. We were not able to ascertain any WT1 level as a confidential marker of molecular remission in either compartment. In relapsed patients, the time period of molecular to hematological relapse was 8–79 days. In the case of molecular relapse, the highest levels of fusion transcripts were in the CD34+BM cells. Twelve patients were treated for 21 molecular relapses; two-thirds of the patient had favorable treatment response. Conclusion. Frequent quantitative monitoring of fusion transcripts (in contrast to WT1) is useful for a reliable prediction of hematological relapse in AML patients. The treatment of molecular relapse of AML may be successful.
ER  -

Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1 (AML1), CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression. \textit{Experimental Hematology}. Int Soc for Exper Hematol, 2009, roč.~37, s.~659-672, 13 s. ISSN~0301-472X.

Přehled o publikaci